{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:33:30Z","timestamp":1792949610425,"version":"4.5.0"},"reference-count":51,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the gel stent\u2019s intraocular pressure (IOP)-lowering safety and effectiveness in angle closure glaucoma (ACG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Prospective, multicenter, nonrandomized, 12-month, interventional study. Adults with ACG (iridotrabecular contact in \u22652 quadrants, glaucomatous optic disc damage, and visual field loss) and baseline IOP 20\u201335 mmHg received ab-interno gel stent implantation on Day 1. The primary endpoint was the proportion of patients achieving \u226520% IOP reduction from baseline without IOP-lowering medication increase at Month 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 62 patients\/eyes enrolled and implanted, 45 (72.6%) had a history of glaucoma procedures, 50 (80.6%) underwent \u22651 concomitant angle-widening procedure(s) (usually cataract surgery), and 59 (95.2%) completed the study. Baseline IOP was 24.0 mmHg on 2.3 IOP-lowering medications (mean). At Month 12, 80.5% (95% confidence interval [CI]: 68.4\u201388.8) of patients achieved the primary endpoint, with similar proportions in the presence (81.8%; 95% CI: 67.3\u201391.8) and absence (83.3%; 95% CI: 51.6\u201397.9) of concomitant angle-widening procedures. Month 12 mean changes from baseline in IOP and number of IOP-lowering medications were \u22128.9 mmHg (95% CI: \u221210.2 to \u22127.6) and \u22121.6 (95% CI: \u22121.9 to \u22121.2), respectively. Twenty-one eyes (33.9%) required needling. There were no surgical complications. Serious postoperative ocular adverse events occurred in 6 (9.7%) study eyes; all resolved without sequelae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Gel stent implantation had an acceptable safety profile and effectively lowered IOP and the medication burden in ACG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261497918","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:38:32Z","timestamp":1792654712000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective, Multicenter, Single-Arm, Open-Label Study of the Safety and Effectiveness of the Gel Stent in Angle Closure Glaucoma"],"prefix":"10.1177","author":[{"given":"Michael","family":"Coote","sequence":"first","affiliation":[{"name":"Royal Victorian Eye and Ear Hospital, Melbourne, Australia."},{"name":"Centre for Eye Research Australia, Melbourne, Australia."},{"name":"Melbourne Eye Specialists, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Kerr","sequence":"additional","affiliation":[{"name":"Royal Victorian Eye and Ear Hospital, Melbourne, Australia."},{"name":"Centre for Eye Research Australia, Melbourne, Australia."},{"name":"Eye Surgery Associates, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harasymowycz","sequence":"additional","affiliation":[{"name":"Bellevue Ophthalmology Clinics, Montreal, Canada."},{"name":"University of Montreal, Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelvin C.A.","family":"Sng","sequence":"additional","affiliation":[{"name":"National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine W.X.","family":"Lun","sequence":"additional","affiliation":[{"name":"National University Hospital, National University Health System, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen-Chieh","family":"Lee","sequence":"additional","affiliation":[{"name":"Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Nagar","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yuan","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Safyan","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-6506","authenticated-orcid":false,"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0951-0416","authenticated-orcid":false,"given":"Susan S.","family":"Lee","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.10.022"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01289-8"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158414221125697"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.07.023"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.03.026"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.624179"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01635-6"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01127-w"},{"key":"e_1_3_3_12_1","volume-title":"ANSI Z80.27-2014. American National Standard for Ophthalmics\u2014Implantable Glaucoma Devices","author":"The Accredited Committee Z80 for Ophthalmic Standards","year":"2014","unstructured":"11.The Accredited Committee Z80 for Ophthalmic Standards. ANSI Z80.27-2014. American National Standard for Ophthalmics\u2014Implantable Glaucoma Devices The Vision Council: Alexandria, VA; 2014."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.10.021"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696"},{"key":"e_1_3_3_15_1","unstructured":"14.International Organization for Standardization. ISO 14155:2020 Clinical investigation of medical devices for human subjects\u2014good clinical practice. Geneva Switzerland; 2020. Available from: https:\/\/www.iso.org\/obp\/ui\/#iso:std:iso:14155:ed-3:v1:en [Last accessed: October10 2023]."},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0000000000000858"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14886"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04251-z"},{"issue":"8","key":"e_1_3_3_19_1","first-page":"2113","article-title":"Evaluation of the XEN45 gel stent in patients with primary angle closure glaucoma","volume":"58","author":"Millan F","year":"2017","unstructured":"18.Millan F, , Reveron ME, , Gonzalez L, et al. Evaluation of the XEN45 gel stent in patients with primary angle closure glaucoma. Invest. Ophthalmol. Vis. Sci 2017;58(8):2113.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30956-4"},{"key":"e_1_3_3_21_1","unstructured":"20.World Glaucoma Association. 3rd Consensus Meeting: Angle Closure and Angle Closure Glaucoma. Amsterdam The Netherlands; 2006. Available from: https:\/\/wga.one\/consensus-3\/ [Last accessed: April1 2025]."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2016.04.21"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2022.2148114"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00639-z"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05189-x"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317303"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3980\/j.issn.2222-3959.2015.04.19"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701477"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.12.032"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13721"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.08.003"},{"key":"e_1_3_3_32_1","unstructured":"31.Allergan Inc. Directions for use for the XEN\u00ae Glaucoma Treatment System. Available from: https:\/\/allergan-web-cdn-prod.azureedge.net\/actavis\/actavis\/media\/allergan-pdf-documents\/labeling\/xen\/dfu_xen_glaucoma_treatment_system_us_feb2017.pdf [Last accessed: April1 2025]."},{"key":"e_1_3_3_33_1","unstructured":"32.AqueSys Inc. Directions for use for the XEN\u202245 Glaucoma Treatment System. Available from: https:\/\/allergan-web-cdn-prod.azureedge.net\/allergancanadaspecialty\/allergancanadaspecialty\/media\/actavis-canada-specialty\/en\/products\/pms\/xen-45-dfu-english-3037-004-rev-a.pdf [Last accessed: April1 2025]."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02022-5"},{"issue":"1","key":"e_1_3_3_35_1","first-page":"44","article-title":"Postoperative complications of Ab-Interno XEN implantation in primary angle closure glaucoma","volume":"10","author":"Asanad S","year":"2021","unstructured":"34.Asanad S, , Kalarn S, , Kaleem MA. Postoperative complications of Ab-Interno XEN implantation in primary angle closure glaucoma. Am J Clin Exp Immunol 2021;10(1):44\u201347.","journal-title":"Am J Clin Exp Immunol"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/opth.S265695"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/opth.S267010"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0192-8"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2022.09.007"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx184"},{"issue":"8","key":"e_1_3_3_41_1","first-page":"668","article-title":"Glaucoma","volume":"93","author":"Gupta D","year":"2016","unstructured":"40.Gupta D, , Chen PP. Glaucoma. Am Fam Physician 2016;93(8):668\u2013674.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"e_1_3_3_43_1","unstructured":"42.Dorairaj S Chan I Teng CC. Diagnosis and management of malignant glaucoma. Available from: https:\/\/www.aao.org\/eyenet\/article\/diagnosis-management-of-malignant-glaucoma [Last accessed: April1 2025]."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001840"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05898-x"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10078-1304"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.021"},{"issue":"8","key":"e_1_3_3_48_1","first-page":"1429","article-title":"Comparison of combined phacotrabeculectomy with trabeculectomy only in the treatment of primary angle-closure glaucoma","volume":"125","author":"Wang M","year":"2012","unstructured":"47.Wang M, , Fang M, , Bai YJ, et al. Comparison of combined phacotrabeculectomy with trabeculectomy only in the treatment of primary angle-closure glaucoma. Chin Med J (Engl) 2012;125(8):1429\u20131433.","journal-title":"Chin Med J (Engl)"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-022-02280-y"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0000000000002172"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2020.11.006"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120979196"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261497918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261497918","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261497918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:47:09Z","timestamp":1792946829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261497918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":51,"alternative-id":["10.1177\/10807683261497918"],"URL":"https:\/\/doi.org\/10.1177\/10807683261497918","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"article-number":"10807683261497918"}}